Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

HIFU (high-intensity focused ultrasound)

Also known as: high-intensity focused ultrasound, microfocused ultrasound, MFU, MFU-V

HIFU uses focused sound energy to heat selected tissue beneath the skin. In aesthetic practice, focused-ultrasound devices are used to improve skin laxity and produce a lifting or tightening effect. The device, treatment area and intended tissue target determine what evidence and safety instructions apply.

In plain English — This treatment concentrates sound energy below the skin to create small areas of heat. Some devices can produce a modest improvement in loose skin, especially around the face and neck. Suitability depends on the area, medical history and the particular device being used.

Evidence status

Emerging

Clinical improvement reported; device-specific evidence. Human studies support improvements in facial and neck laxity with particular focused-ultrasound systems. Much of the evidence consists of uncontrolled studies with follow-up measured in months, and a major meta-analysis was manufacturer-funded. Device selection, realistic goals and complication recognition remain central to practice.

What HIFU is, and the types available#

HIFU stands for high-intensity focused ultrasound. A transducer concentrates sound energy within a selected tissue region, creating heat below the skin surface. In aesthetic practice, focused-ultrasound systems are used for tissue tightening and lifting. The terms intense focused ultrasound, microfocused ultrasound (MFU) and MFU with visualisation (MFU-V) occur throughout the clinical literature.[1, 4, 5]i[2, 4, 5]i

An imaging-equipped system can help the operator identify tissue layers and check contact before energy delivery. Device names matter: systems differ in their focal geometry, imaging capability, intended target and supporting studies. A treatment offered under the broad HIFU label needs to be identified more precisely before its likely effects can be discussed. Other ultrasound facial applications are covered in ultrasound facial.[2, 4, 5]i

Use of HIFU in aesthetic practice#

The principal consultation is about laxity: the location and degree of looseness, the amount of change the person hopes to see, and whether the chosen system is intended for that area. Device instructions, competence, insurance, premises requirements and a route to medical complication care all need to be established before offering treatment.[1, 2, 4]i

UK scope must be checked by nation. The following is a dated orientation, checked on 16 September 2026, rather than permission to practise:

  • England: the August 2025 DHSC response sets out plans to develop licensing and restrictions, with further work on procedure categories and practitioner requirements. That response does not itself bring a new licence into operation. Confirm the current position and any existing local requirements for the service.[7]
  • Scotland:S.S.I. 2026/87 explicitly includes defined HIFU procedures. Article 4 does not require the licence before 6 September 2027; article 6 contains transitional arrangements for qualifying applications. The Order’s definitions and exclusions determine its application to a particular service.[8]
  • Wales: the current special-procedures licensing guidance names acupuncture, body piercing, electrolysis and tattooing. It is not a general HIFU authorisation; the applicable requirements for the actual service need separate confirmation.[9]i
  • Northern Ireland: the Minister of Health stated in April 2026 that there were no current plans for a broad non-surgical cosmetic licensing scheme in the remaining mandate. This is a policy statement, not an exemption from existing obligations.[10]i

Contraindications and cautions#

Screen against the specific model’s current instructions for the relevant market. As a documented example, the manufacturer’s 2026 US Ulthera PRIME instructions contraindicate use where there are open wounds or lesions, severe/cystic acne, active implants or relevant metallic implants.[4]

The same instructions classify pregnancy/breastfeeding, anticoagulation and several conditions affecting healing as unevaluated, and advise against direct treatment over fillers, relevant implants or an existing keloid. These distinctions matter: an unevaluated population is not established safe. The eye and other vulnerable anatomy require device-specific protection and training. This is an assessment summary, not a complete contraindication checklist.[4]

Clinical uses and the evidence behind them#

Facial and neck laxity

The best-developed clinical role is improvement of mild-to-moderate facial and neck laxity. In Contini and colleagues’ 2023 systematic review, most participants were women and the studies used several different systems. Improvements were assessed through photographs, measurements and patient or clinician ratings; the outcomes describe modest changes rather than surgical repositioning.[1, 2, 3]i

One useful primary example is Alam and colleagues’ prospective cohort. It enrolled 36 adults, including 34 women, aged 32–62 years, with 35 evaluated after face and neck treatment. At 90 days, mean brow-height elevation on photographs was 1.7 mm. Assessors were masked, but there was no untreated comparison group; the retrieved abstract did not establish the study’s funding. This gives a concrete sense of the scale and location of an observed change.[3]

Broader improvement and other treatment areas

Amiri and colleagues’ review, published online in 2024 and in a 2025 issue, found improvements in investigator and patient ratings across studies of adults’ faces, necks and selected body areas. It was funded by Merz North America, and several authors disclosed commercial relationships with Merz. Its 42 studies were predominantly uncontrolled; most followed participants for no more than six months, and the pooled analyses used treated pre/post data. These findings support discussing possible improvement while leaving substantial uncertainty about comparative effectiveness and durability.[2]

The manufacturer’s current US Ulthera instructions include selected facial, neck, décolleté and body-laxity indications. Those are named-product indications, and research on one area should not substitute for evidence about another. Particularly extensive laxity or a desired large change calls for discussion of other options and, where appropriate, specialist assessment.[1, 2, 4]i

Selecting a focused-ultrasound treatment#

Start with the target: laxity, wrinkles, surface texture and loss of facial volume are different observations. Record the person’s priorities, examine the tissue distribution, and establish what a worthwhile outcome would look like. Baseline photographs should use reproducible positioning and lighting so follow-up can assess the original concern.[1, 2, 3]i

The selection then needs to resolve:

  • The exact system and its intended use for that body area, including whether it provides imaging.[2, 4, 5]i
  • Skin condition, relevant medical history, implants, previous filler or other procedures, and any reason to defer.[4]
  • The likely magnitude and timing of change, the possibility of little improvement, discomfort and the follow-up plan.[1, 2, 3]i
  • Who will assess and manage a suspected complication, including a clear route to medical care.[4]i

Energy, cartridge choice and anatomical treatment planning belong to the model’s instructions and supervised training. No treatment protocol is supplied here.

Adverse effects and their management#

Expected reactionsinclude pain, redness, swelling, tenderness and bruising. The clinical reviews describe these commonly; the manufacturer’s instructions also discuss transient sensory or motor nerve effects. Recovery advice and review arrangements should be specific to the device and presentation.[2, 4]

Injury or unexpected change needs a different response. Burns, blistering, persistent pain, new weakness, altered sensation or a developing contour change require clinical assessment rather than automatic reassurance. The current manufacturer instructions list post-market reports including fat/volume loss, asymmetry, pigment change and neurological or visual symptoms. These voluntary reports have uncertain frequency and do not establish causality in every case.[4][4]i

Stop further treatment when a complication is suspected, document the device and event, arrange appropriate medical assessment, and follow the applicable reporting route.[4]i

Referral and scope boundaries#

Refer before treatment when the desired change exceeds what the chosen system can reasonably address, the anatomy or medical history is outside competence, or an unexplained lesion needs diagnosis. An accountable clinician should resolve significant contraindication or complication concerns.[1, 2, 4]i

After treatment, visual symptoms or sudden focal neurological symptoms need emergency assessment; they should not be presumed to be a routine cosmetic reaction. Persistent pain, burns, weakness, numbness or new asymmetry also warrant prompt clinical review. A skincare professional’s role includes recognising these presentations and escalating them, not diagnosing a nerve injury from appearance alone.[4]i

Mechanism of action#

Absorbed focused acoustic energy creates local points of thermal coagulation. Collagen alteration and subsequent tissue remodelling provide a rationale for a tightening effect; imaging, where available, helps locate the intended tissue region.[1, 4, 6]i

An early primary experiment by White and colleagues demonstrated targeted thermal injury and shrinkage in the facial superficial musculoaponeurotic system (SMAS) in six unfixed human cadaver specimens. The work was partly funded by Ulthera, involved company stockholders and technology developers, and the sponsor participated in the research and writing. It establishes an ex-vivo tissue effect, not living-patient healing or a quantified long-term clinical result.[1, 4, 6]i

Commonly misstated claims#

A response percentage turned into an amount of tightening

Claim heard:“HIFU gives 89% tightening.”

Literature finding:Amiri’s pooled investigator-rated result was 89% of patients with some improvement(95% CI 81–94%; 411 patients; I² 63%). It combined improvement categories, including mild improvement, from treated pre/post data.[2]

Supported statement: Most participants in that pooled analysis were graded as improved; the figure does not measure how much their skin tightened.

Area measurements described as lifting distances

Claim heard:“A study showed the neck lifted by tens of millimetres.”

Literature finding:Some submental outcomes in Contini’s review are photographic area changes, measured in square millimetres. They are not vertical distances.[1]

Supported statement: Describe the actual measurement and its units; photographic area change cannot be reported as millimetres of neck lift.

Follow-up percentages treated as one continuing cohort

Claim heard:“The same group kept improving throughout a full year.”

Literature finding:Contini’s pooled patient-rating table contains 81 participants at day 90 but only 19 at one year. The percentages at those time points do not follow one intact group.[1]

Supported statement: A one-year observation in a small sample should be described as such, without manufacturing a continuous improvement trajectory.

One clearance extended to a device category

Claim heard:“FDA clearance proves all HIFU machines deliver the same result.”

Literature finding: K233996 is a February 2024 clearance for the named Ulthera PRIME console and the specified indications at that date. Its console changes were supported by non-clinical performance testing. The current manufacturer instructions include later indication information, so that older record is not an exhaustive current list either.[5]i

Supported statement: Identify the model, document and indication; a clearance for one system is not comparative clinical evidence for every machine sold as HIFU.

Areas of remaining uncertainty#

  • Which baseline features best predict a worthwhile change? Record laxity, tissue distribution and the person’s priority so that follow-up can inform future selection.[1, 2, 3]i[2]
  • What outcome would justify repeating treatment for this individual? Agree the review criteria before discussing a maintenance plan.[2]

Frequently asked questions#

What should a client bring to the consultation?

A medical and procedure history, including implants and previous injectable treatment. Identifying the relevant area and desired change helps the clinician assess whether a focused-ultrasound approach fits the concern.[1, 2, 4]i

How should results be reviewed?

Against the original concern using comparable photographs and the person’s own assessment. Many studies assessed change over several months, so an immediate post-treatment photograph alone is an inadequate follow-up plan.[1, 2, 3]i

Does visualisation matter when choosing a service?

It is a specific capability worth identifying. On the documented Ulthera system, imaging helps assess tissue and coupling; the word HIFU on a treatment menu does not specify whether that capability is present.[2, 4, 5]i

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Contini M, Hollander MHJ, Vissink A, Schepers RH, Jansma J, Schortinghuis J. A Systematic Review of the Efficacy of Microfocused Ultrasound for Facial Skin Tightening. International Journal of Environmental Research and Public Health. 2023;20(2):1522. doi:10.3390/ijerph20021522. PMID:36674277.Tier 1Supports: Sixteen studies of facial tightening, device variation, predominantly female populations with mild/moderate laxity, objective photographic measurements and changing follow-up denominators. Last search update June 2021.Funding / interest: Authors state no external funding and no conflicts of interest. This disclosure does not establish independence of each included device study.
  2. Amiri M, Ajasllari G, Llane A, et al. Microfocused Ultrasound With Visualization (MFU-V) Effectiveness and Safety: A Systematic Review and Meta-Analysis. Aesthetic Surgery Journal. 2025;45(3):NP86–NP94. Published online 14 November 2024. doi:10.1093/asj/sjae228. PMID:39540440.Tier 1Supports: Forty-two studies, mostly pre/post designs; pooled any-improvement estimates with CIs and heterogeneity; all meta-analyses use treated pre/post data, including treated arms extracted from controlled trials. Searches through August 2023.Funding / interest: Funded by Merz North America, Inc. Multiple authors report Merz consulting/speaking relationships; other commercial relationships and an Epistudia stock interest are disclosed. Amiri, Ajasllari and Llane report no disclosures.
  3. Alam M, White LE, Martin N, Witherspoon J, Yoo S, West DP. Ultrasound tightening of facial and neck skin: a rater-blinded prospective cohort study. Journal of the American Academy of Dermatology. 2010;62(2):262–269. doi:10.1016/j.jaad.2009.06.039. PMID:20115948.Tier 3Supports: Thirty-six adults enrolled, 34 women, 35 evaluated; ages 32–62, median 44; face/neck treatment, photographic brow-height change at 90 days. Uncontrolled cohort with masked assessors, not a randomised comparison.Funding / interest: Specific funding and conflicts were not available in the personally retrieved complete official abstract/core record; unknown, not assumed independent.
  4. Ulthera, Inc. Ulthera System Instructions for Use, featuring DeepSEE Technology for Ultherapy PRIME. US edition, document 1016413IFU Rev00, copyright 2026. Medical Safety sections 2.1–2.7 and System Description 3.1. Accessed 16 September 2026.Tier 4Supports: Current manufacturer US intended uses, contraindications versus unevaluated populations, tissue-heating/imaging function, clinical reactions and post-market events with uncertain frequency and causality. Not UK operator law.Funding / interest: Manufacturer-authored instructions from Ulthera/Merz; authoritative for this product's stated instructions, not independent comparative clinical evidence.
  5. US Food and Drug Administration. K233996: Ulthera System (UC-1 Control Unit PRIME), substantial-equivalence letter and 510(k) summary. 22 February 2024.Tier 1Supports: Named-device US clearance, defined indications at that date, imaging purpose and console modification supported by non-clinical performance tests. Not a current exhaustive indication list or a UK permission to practise.Funding / interest: FDA decision incorporating the commercial applicant Ulthera's submission. Regulatory status rather than an independent efficacy trial.
  6. White WM, Makin IRS, Barthe PG, Slayton MH, Gliklich RE. Selective creation of thermal injury zones in the superficial musculoaponeurotic system using intense ultrasound therapy: a new target for noninvasive facial rejuvenation. Archives of Facial Plastic Surgery. 2007;9(1):22–29. doi:10.1001/archfaci.9.1.22. PMID:17224484.Ex vivoTier 3Supports: Six unfixed human cadaver specimens: targeted facial SMAS thermal injury and tissue shrinkage, with surrounding tissue relatively spared. Ex-vivo mechanism, not living-patient recovery or durable clinical lifting.Funding / interest: Part-funded by Ulthera. Makin, Barthe and Slayton were Ulthera stockholders and technology developers; sponsor participated in design, collection, analysis and writing. Disclosures personally retrieved from publisher.
  7. Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England: consultation response. 7 August 2025. Accessed 16 September 2026.Tier 1Supports: England-only policy intentions, further consultation and regulatory development; proposed procedure categories and restrictions are not made operative by the response itself.Funding / interest: UK government policy document; not a clinical study.
  8. Scottish Ministers. Civic Government (Scotland) Act 1982 (Licensing of Non-surgical Procedures) Order 2026. S.S.I. 2026/87, articles 3–6 and schedule 1 paragraph 5.Tier 1Supports: Express HIFU definition and Scottish licensing framework, with article 4(2) not requiring the licence before 6 September 2027 and article 6 transitional provision. Application and exclusions must be checked.Funding / interest: Primary Scottish legislation; not a clinical study.
  9. Welsh Government. Licensing scheme for special procedures. Updated 30 July 2026. Accessed 16 September 2026.Tier 1Supports: Welsh mandatory scheme covers four named procedures: acupuncture, body piercing, electrolysis and tattooing. It is not a general HIFU licensing document.Funding / interest: Welsh Government regulatory guidance; not a clinical study.
  10. Northern Ireland Assembly. AQW 41857/22–27: non-surgical aesthetic procedure licensing. Minister of Health answer, 1 April 2026.Tier 1Supports: Minister reported no current plans for a broad non-surgical cosmetic licensing scheme in the remaining mandate; not a statement that existing legal duties are absent.Funding / interest: Official parliamentary answer; not a clinical study.